



Istodax[®] (romidepsin) – First-time generic

- On January 11, 2018, Pfizer launched an authorized generic version of Celgene's [Istodax \(romidepsin\)](#) 10 mg injection.
- Istodax is approved for the treatment of cutaneous T-cell lymphoma in patients who have received at least one prior systemic therapy; and peripheral T-cell lymphoma in patients who have received at least one prior therapy.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.